{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:05:49Z","timestamp":1781629549003,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Borderline ovarian tumors (BOTs) constitute a category of non-invasive epithelial neoplasms of the ovary, characterized by a substantially more favorable prognosis in comparison to their invasive malignant counterparts. Given their prevalence among young women, balancing oncologic safety with fertility preservation is critical for clinical management. This study evaluates factors associated with survival in patients with BOTs over a long-term follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective cohort study examined data from 135 patients diagnosed with borderline ovarian tumors (BOTs) between January 2000 and December 2023 at medical centers associated with Urmia University of Medical Sciences. Clinical and histopathological parameters were carefully extracted from both electronic and paper-based medical records. Overall survival rates were estimated using the Kaplan-Meier method, and intergroup comparisons were performed with the log-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean patient age was 39.5 years; with most cases diagnosed at FIGO stage I (94.1%). Conservative surgical management was performed in 65.2% of patients, while 34.8% underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH\u2009+\u2009BSO). Survival rates at 1, 3, 5, and 10 years were 100%, 99.2%, 98.3%, and 97.2%, respectively. No statistically significant differences in survival were observed based on age)\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.442(, tumor size (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.752), bilaterality (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.969), Histopathology (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.069), FIGO stage (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.746), or surgical approach (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.199).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Borderline ovarian tumors (BOTs) typically manifest a benign clinical trajectory, with conservative surgical approaches demonstrating both safety and efficacy, especially in women of reproductive age. The absence of correlations between select histopathological characteristics and survival outcomes underscores the need to avoid unnecessary surgical procedures, thereby optimizing patient-centered care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-025-04183-3","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:16:32Z","timestamp":1765523792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival analysis of borderline ovarian tumors: a 23-year retrospective study in a Middle Eastern cohort"],"prefix":"10.1186","volume":"25","author":[{"given":"Haleh","family":"Ayatollahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayna","family":"Abbaszadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedigheh","family":"Ghasemian Dizaj Dehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Khalkhali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Babajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"11","key":"4183_CR1","doi-asserted-by":"publisher","first-page":"6714","DOI":"10.1245\/s10434-021-09879-y","volume":"28","author":"G Ricotta","year":"2021","unstructured":"Ricotta G, Maulard A, Genestie C, Pautier P, Leary A, Chargari C, et al. Brenner borderline ovarian tumor: a case series and literature review. Ann Surg Oncol. 2021;28(11):6714\u201320.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"4183_CR2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.ejca.2013.01.035","volume":"49","author":"A du Bois","year":"2013","unstructured":"du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, et al. Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gyn\u00e4kologische Onkologie (AGO) Study Group. Eur J Cancer. 2013;49(8):1905\u201314.","journal-title":"Eur J Cancer"},{"issue":"7","key":"4183_CR3","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/annonc\/mdu119","volume":"25","author":"F Trillsch","year":"2014","unstructured":"Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, et al. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Ann Oncol. 2014;25(7):1320\u20137.","journal-title":"Ann Oncol"},{"issue":"9 Suppl 3","key":"4183_CR4","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1097\/IGC.0000000000000282","volume":"24","author":"P Harter","year":"2014","unstructured":"Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, et al. Gynecologic cancer intergroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer. 2014;24(9 Suppl 3):S5\u20138.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"4183_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ygyno.2020.02.007","volume":"157","author":"H Plett","year":"2020","unstructured":"Plett H, Harter P, Ataseven B, Heitz F, Prader S, Schneider S, et al. Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors. Gynecol Oncol. 2020;157(2):411\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4183_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2020.101965","volume":"50","author":"C Huchon","year":"2021","unstructured":"Huchon C, Bourdel N, Abdel Wahab C, Aza\u00efs H, Bendifallah S, Bolze PA, et al. Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkers. J Gynecol Obstet Hum Reprod. 2021;50(1):101965.","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"1","key":"4183_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1006\/gyno.2002.6711","volume":"86","author":"CL Trimble","year":"2002","unstructured":"Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol. 2002;86(1):34\u20137.","journal-title":"Gynecol Oncol"},{"key":"4183_CR8","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.2147\/CMAR.S250394","volume":"12","author":"Y Sun","year":"2020","unstructured":"Sun Y, Xu J, Jia X. The diagnosis, treatment, prognosis and molecular pathology of borderline ovarian tumors: current status and perspectives. Cancer Manage Res. 2020;12:3651\u20139.","journal-title":"Cancer Manage Res"},{"issue":"1","key":"4183_CR9","doi-asserted-by":"publisher","DOI":"10.4081\/ejtm.2022.10779","volume":"33","author":"SRY Sharami","year":"2022","unstructured":"Sharami SRY, Farhadifar F, Tabatabaei R. Recurrence and 5-year survival rate in patients with borderline ovarian tumors and related factors in Kurdistan. Eur J Transl Myol. 2022;33(1):10779.","journal-title":"Eur J Transl Myol"},{"key":"4183_CR10","volume":"264","author":"G Scaglione","year":"2024","unstructured":"Scaglione G, Travaglino A, Raffone A, Santoro A, Arciuolo D, Fulgione C, et al. Micropapillary pattern in serous borderline ovarian tumor and the risk of extraovarian localization of low-grade serous carcinoma (\u2018invasive implants\u2019): a systematic review and meta-analysis. Pathology. 2024;264:155714.","journal-title":"Pathology"},{"issue":"2","key":"4183_CR11","first-page":"57","volume":"4","author":"M Karimi Zarchi","year":"2022","unstructured":"Karimi Zarchi M, Mehdizadeh Kashi A, Allahqoli L, Sadat Tabatabai R, Shamsi F, Hashemian Asl N. The recurrence and 5-year survival rates in patients with borderline ovarian tumors in Yazd from 2006 to 2016. J Obstet Gynecol Cancer Res. 2022;4(2):57\u201361.","journal-title":"J Obstet Gynecol Cancer Res"},{"issue":"13","key":"4183_CR12","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.3390\/healthcare11131922","volume":"11","author":"B Pecorino","year":"2023","unstructured":"Pecorino B, Lagan\u00e0 AS, Mereu L, Ferrara M, Carrara G, Etrusco A, et al. Evaluation of borderline ovarian tumor recurrence rate after surgery with or without fertility-sparing approach: results of a retrospective analysis. Healthcare. 2023;11(13):1922.","journal-title":"Healthcare"},{"issue":"1","key":"4183_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ygyno.2016.05.005","volume":"142","author":"NMS Karlsen","year":"2016","unstructured":"Karlsen NMS, Karlsen MA, H\u00f8gdall E, Nedergaard L, Christensen IJ, H\u00f8gdall C. Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). Gynecol Oncol. 2016;142(1):50\u20133.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4183_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.fertnstert.2020.07.043","volume":"115","author":"G Johansen","year":"2021","unstructured":"Johansen G, Dahm-K\u00e4hler P, Staf C, R\u00e5destad AF, Rodriguez-Wallberg KA. Reproductive and obstetrical outcomes with the overall survival of fertile-age women treated with fertility-sparing surgery for borderline ovarian tumors in Sweden: a prospective nationwide population-based study. Fertil Steril. 2021;115(1):157\u201363.","journal-title":"Fertil Steril"},{"issue":"1","key":"4183_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3802\/jgo.2013.24.1.44","volume":"24","author":"T Song","year":"2013","unstructured":"Song T, Lee YY, Choi CH, Kim TJ, Lee JW, Bae DS, et al. Histologic distribution of borderline ovarian tumors worldwide: a systematic review. J Gynecol Oncol. 2013;24(1):44\u201351.","journal-title":"J Gynecol Oncol"},{"issue":"12","key":"4183_CR16","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1634\/theoncologist.2012-0139","volume":"17","author":"D Fischerova","year":"2012","unstructured":"Fischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, treatment, and follow-up of borderline ovarian tumors. Oncologist. 2012;17(12):1515\u201333.","journal-title":"Oncologist"},{"issue":"4","key":"4183_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/aogs.12846","volume":"95","author":"G Kalapotharakos","year":"2016","unstructured":"Kalapotharakos G, H\u00f6gberg T, Bergfeldt K, Borgfeldt C. Long-term survival in women with borderline ovarian tumors: a population-based survey of borderline ovarian tumors in Sweden 1960\u20132007. Acta Obstet Gynecol Scand. 2016;95(4):473\u20139.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"5","key":"4183_CR18","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/IGC.0b013e31824b4076","volume":"22","author":"T Song","year":"2012","unstructured":"Song T, Lee Y-Y, Choi CH, Kim T-J, Lee J-W, Kim B-G, et al. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors. Int J Gynecol Cancer. 2012;22(5):770\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"4183_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2214\/AJR.09.3936","volume":"194","author":"N Lalwani","year":"2010","unstructured":"Lalwani N, Shanbhogue AK, Vikram R, Nagar A, Jagirdar J, Prasad SR. Current update on borderline ovarian neoplasms. AJR Am J Roentgenol. 2010;194(2):330\u20136.","journal-title":"AJR Am J Roentgenol"},{"key":"4183_CR20","doi-asserted-by":"crossref","unstructured":"Bonadio RC, de Siqueira Santos AG, Estevez-Diz MDP. Borderline ovarian tumors: a review of its biology, molecular profile, and management. Brazilian J Oncol. 2024;20:e\u201320230437.","DOI":"10.5935\/2526-8732.20230437"},{"issue":"11","key":"4183_CR21","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1097\/01.pas.0000213294.81154.95","volume":"30","author":"EG Silva","year":"2006","unstructured":"Silva EG, Gershenson DM, Malpica A, Deavers M. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol. 2006;30(11):1367\u201371.","journal-title":"Am J Surg Pathol"},{"key":"4183_CR22","doi-asserted-by":"crossref","unstructured":"Atallah D, El Feghaly I, Choueiry E, Jalkh N, Khaddage A, Akiki M, et al. 618\u2005Genetic profile by whole exome sequencing of borderline ovarian tumors: series of 32 patients.International Journal of Gynecological Cancer. 2021;31:A256\u2013A7.","DOI":"10.1136\/ijgc-2021-ESGO.439"},{"issue":"13","key":"4183_CR23","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/cancers16132322","volume":"16","author":"A Badlaeva","year":"2024","unstructured":"Badlaeva A, Tregubova A, Palicelli A, Asaturova A. Eosinophilic cells in ovarian borderline serous tumors as a predictor of BRAF mutation. Cancers. 2024;16(13):2322.","journal-title":"Cancers"},{"issue":"2","key":"4183_CR24","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3892\/ol.2014.2758","volume":"9","author":"V Loizzi","year":"2015","unstructured":"Loizzi V, Selvaggi L, Leone L, Latorre D, Scardigno D, Magazzino F, et al. Borderline epithelial tumors of the ovary: experience of 55 patients. Oncol Lett. 2015;9(2):912\u20134.","journal-title":"Oncol Lett"},{"issue":"3","key":"4183_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.38053\/acmj.1243317","volume":"5","author":"F Sahin","year":"2023","unstructured":"Sahin F, Akt\u00fcrk E, G\u00fcnkaya OS, \u00d6zdemir S, Konal M, Gen\u00e7 S, et al. Borderline ovarian tumors: twenty years of experience at a tertiary center. Anatol Curr Med J. 2023;5(3):196\u2013200.","journal-title":"Anatol Curr Med J"},{"issue":"2","key":"4183_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ygyno.2012.02.017","volume":"125","author":"J Menczer","year":"2012","unstructured":"Menczer J, Chetrit A, Sadetzki S. The effect of hysterectomy on survival of patients with borderline ovarian tumors. Gynecol Oncol. 2012;125(2):372\u20135.","journal-title":"Gynecol Oncol"},{"key":"4183_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11131922","author":"B Pecorino","year":"2023","unstructured":"Pecorino B, Lagan\u00e0 AS, Mereu L, Ferrara M, Carrara G, Etrusco A, et al. Evaluation of borderline ovarian tumor recurrence rate after surgery with or without fertility-sparing approach: results of a retrospective analysis. Healthcare. 2023. https:\/\/doi.org\/10.3390\/healthcare11131922.","journal-title":"Healthcare"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-04183-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-025-04183-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-025-04183-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:27:11Z","timestamp":1781627231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-025-04183-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4183"],"URL":"https:\/\/doi.org\/10.1186\/s12905-025-04183-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7168557\/v1","asserted-by":"object"}]},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"20 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was conducted by the Institutional Ethics Committee for Human Research at Urmia University of Medical Sciences in accordance with the Declaration of Helsinki and with the receipt of (Ethics Code: IR.UMSU.REC.1401.119).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"614"}}